GroupM, Kochava, MetaX, and Nyiax have become member companies in an IAB Tech Lab working group that launched Monday focused on blockchain and explore ways to use it in digital technology. ShailleySingh leads the group. The working group will initially design ways to educate the industry, set priorities for business use cases and develop standards and best practices.
NYS Entity Status
NYS Filing Date
APRIL 28, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - JOA DEVELOPMENT GROUP INC.
Around the Web
- IAB Tech Lab Launches Blockchain Working Group
Monday Sep 18, 2017
- Solar Developers and Panel Makers Clash Over Tariff Request
By DIANE CARDWELL - Tuesday Aug 15, 2017
Troubled domestic manufacturers say cheap Chinese products have undercut their own, but industry groups are urging a trade panel to reject sanctions.
- Aimmune in Brisbane teams with Regeneron to find peanut allergy cure
By Caroline Chen - Tuesday Oct 17, 2017
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies. Aimmune, based in Brisbane, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends. “What we’re learning is that the immune system does seem to be plastic, and with the right group, you can turn the disease back,” Aimmune’s chief executive officer, Stephen Dilly, said.
- This New Ad Campaign Shows The Faces Of Global Poverty–And Opportunity
By Eillie Anzilotti - Tuesday Oct 17, 2017
For World Poverty Day, nonprofit venture capital fund Acumen debuts a series of portraits of people living on less than $5 a day–and show how the projects it’s funded are helping.
“We live in a moment right now when divides between people are sharp, and growing,” Jacqueline Novogratz, founder and CEO of the nonprofit venture capital fund Acumen, which invests philanthropic capital to support business growth in the developing world. But, she adds, if you pause and look more closely at people, those divides start to blur, then fall away entirely.
- Restaurant Review: The Pool Strives to Deal With Its Famous Dining Room
By PETE WELLS - Tuesday Oct 17, 2017
Changes to the landmark interior of the former Four Seasons create challenges for the new restaurant from Major Food Group.
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.